TriSalus Life Sciences, Inc. (NASDAQ:TLSI - Get Free Report) saw a significant growth in short interest during the month of December. As of December 15th, there was short interest totalling 57,600 shares, a growth of 22.8% from the November 30th total of 46,900 shares. Approximately 1.7% of the shares of the company are sold short. Based on an average daily volume of 35,900 shares, the days-to-cover ratio is currently 1.6 days.
Analyst Ratings Changes
Several research analysts have recently commented on TLSI shares. Roth Mkm started coverage on shares of TriSalus Life Sciences in a report on Monday, November 11th. They set a "buy" rating and a $11.00 target price on the stock. Northland Capmk raised TriSalus Life Sciences to a "strong-buy" rating in a report on Friday, October 25th. Northland Securities began coverage on TriSalus Life Sciences in a report on Friday, October 25th. They set an "outperform" rating and a $12.50 target price on the stock. Cantor Fitzgerald assumed coverage on TriSalus Life Sciences in a research note on Tuesday, December 17th. They issued an "overweight" rating and a $10.00 price target for the company. Finally, Oppenheimer started coverage on shares of TriSalus Life Sciences in a report on Monday, September 16th. They issued an "outperform" rating and a $10.00 target price on the stock. Seven investment analysts have rated the stock with a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $11.79.
Get Our Latest Report on TLSI
TriSalus Life Sciences Stock Down 3.0 %
Shares of TLSI stock traded down $0.15 on Friday, reaching $4.84. The company had a trading volume of 57,126 shares, compared to its average volume of 39,959. The stock has a market capitalization of $147.59 million, a PE ratio of -1.94 and a beta of 0.56. The business's 50-day moving average is $4.17 and its 200 day moving average is $4.85. TriSalus Life Sciences has a one year low of $3.50 and a one year high of $10.42.
Insider Activity
In other TriSalus Life Sciences news, major shareholder Equity Ab Frankenius purchased 62,972 shares of the firm's stock in a transaction that occurred on Tuesday, December 17th. The shares were acquired at an average cost of $3.97 per share, for a total transaction of $249,998.84. Following the completion of the purchase, the insider now owns 6,230,748 shares of the company's stock, valued at approximately $24,736,069.56. The trade was a 1.02 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders have bought 70,012 shares of company stock valued at $281,235. 32.80% of the stock is owned by insiders.
Hedge Funds Weigh In On TriSalus Life Sciences
Several institutional investors and hedge funds have recently added to or reduced their stakes in TLSI. Duquesne Family Office LLC increased its holdings in shares of TriSalus Life Sciences by 35.1% during the second quarter. Duquesne Family Office LLC now owns 426,921 shares of the company's stock worth $2,357,000 after buying an additional 110,966 shares in the last quarter. Highbridge Capital Management LLC acquired a new position in TriSalus Life Sciences in the 2nd quarter worth about $1,184,000. Geode Capital Management LLC increased its holdings in TriSalus Life Sciences by 45.4% in the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company's stock worth $924,000 after purchasing an additional 62,542 shares in the last quarter. Wolverine Asset Management LLC acquired a new stake in shares of TriSalus Life Sciences during the second quarter valued at about $240,000. Finally, MSD Partners L.P. bought a new stake in shares of TriSalus Life Sciences during the third quarter worth about $184,000. Institutional investors own 2.58% of the company's stock.
About TriSalus Life Sciences
(
Get Free Report)
TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.
Further Reading
Before you consider TriSalus Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TriSalus Life Sciences wasn't on the list.
While TriSalus Life Sciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
